Percutaneous Coronary Interventions in Cardiac Allograft Vasculopathy: A Single-Center Experience

Drug‐Eluting Stents May Not Reduce Target Lesion Revascularization in Cardiac Allograft Vasculopathy

“…Our findings are hypothesis generating and suggest that treatment with DES may not necessarily provide an advantage in this population of patients when compared with BMS. A limited number of studies have been performed to directly compare DES with BMS in this unique population, and results have been mixed, although most demonstrated a trend toward a reduction in ISR, although not statistically significant possibly due to small sample size . Most studies in the literature also have not demonstrated a clear reduction in TLR or clinical outcomes.…”

Drug eluting versus bare metal stents in cardiac allograft vasculopathy

“…In small scale studies such as these, a small loss in follow‐up will skew the results significantly. Another recent retrospective study by Colombo et al, showed that the use of DES may significantly reduce the risk of ISR in CAV [32]. Until recently not much of information was available on the direct comparison of different kinds of DES in the treatment of CAV.…”

Clinical and Angiographic Outcomes with Everolimus Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy

“…However, the angiographic follow‐up in this latter study was only 71%. Table shows a comparison of angiographic outcomes in recent studies of DES for TCAD . Only studies with ≥60% angiographic follow‐up were included; however, none of these studies included analysis of EES.…”